References
- Garratty G. Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of tramsfusion reactions. Arlington, VA: American Association of Blood Banks, 1982:91–119.
- Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449–52.
- Shoeppncr-Estey S, Girin J, Mallory D, Davey R, A comparison of the monocyte monolayer assay to the 51Chromium (51Cr) red cell survival for determining the clinical significance of red cell alloantibodies (abstract). Blood 1986;68:302a.
- Baldwin ML, Ness PM, Barrasso C, et al. In vivo studies of long term 51Cr red cell survival for determining the clinical significance of red cell alloantibodies. Transfusion 1985;25:34–8.
- Eaton BR. Morton JA, Pickles MM, White KE. A new antibody. anti-Yta, characterizing a blood group antigen of high incidence. Br J Haematol 1956;2:333–41.
- Dobbs JV, Prutting DL, AdebahrMA. Allen EH, Alter AA. Clinical experience with three examples of anti-Yta. Vox Sang 1968; 15:216–21.
- Bettigole R, Hams JP, Tegoli J, Issitt PD. Rapid in vivo destruction of Yt(a+) red cells in a patient with anti-Yta. Vox Sang 1968;14:143–6.
- Gobel U, Drescher KH, Pottgen W, Lehr HJ. A second example of anti-Yta with rapid in vivo destruction of Yta red cells. Vox Sang 1974;27:171–5.
- International Committee for Standardization in Hematology. Recommended methods for radioisotope red cell survival studies. Blood 1971;38:378–86.
- Issitt PD. Applied blood group serology, 3rd ed. Miami, FL: Montgomery Scientific Publications. 1985:387–8.
- AuBuchon JP, Brightman A, Anderson HA, Kim B. An example of anti-Yta demonstrating a change in its clinical significance. Vox Sang 1988;55:171–5.
- Davey RJ, Simpkins SS. 51Chromium survival of Yt(a+) red cells as a determinant of the in vivo significance of anti-Yta. Transfusion 1982;21:702–5.